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SUMMARY
Background
The efﬁcacy of rifaximin, a nonsystemic, gut-targeted antibiotic for reduc-
ing non–constipation-predominant irritable bowel syndrome (non-C IBS)
symptoms, has been demonstrated in one phase 2b and two phase 3
randomised, double-blind, placebo-controlled trials, but detailed data about
rifaximin safety and tolerability during treatment and subsequent follow-up
periods are lacking.
Aim
To assess and determine the frequency of rifaximin and placebo adverse
events (AEs) in phase 2b and phase 3 non-C IBS trials.
Methods
A post hoc pooled safety analysis of the phase 2b (rifaximin 275, 550, and
1100 mg twice daily for 2 weeks; 550 mg twice daily for 4 weeks) and
phase 3 (rifaximin 550 mg three times daily for 2 weeks) studies was per-
formed. Data on treatment and post-treatment AEs were collected. Patients
were followed up for 12 weeks and 10 weeks post-treatment in the phase
2b and phase 3 trials, respectively.
Results
Patients receiving rifaximin (n = 1103) and placebo (n = 829) had a similar
incidence of drug-related AEs (12.1% vs. 10.7%), serious AEs (1.5% vs. 2.2%),
drug-related AEs resulting in study discontinuation (0.8% vs. 0.8%), gastroin-
testinal-associated AEs (12.2% vs. 12.2%) and infection-associated AEs (8.5%
vs. 9.5%). There were no cases of Clostridium difﬁcile colitis or deaths.
Conclusions
The safety and tolerability proﬁle of rifaximin during treatment and post-
treatment was comparable to placebo. Future research should deﬁne
the safety and tolerability proﬁle, including risk of C. difﬁcile colitis and
microbial antibiotic resistance, with repeated courses of rifaximin in
patients with non—constipation-predominant irritable bowel syndrome
(ClinicalTrials.gov: NCT00269412, NCT00731679, and NCT00724126).
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INTRODUCTION
Irritable bowel syndrome (IBS) manifests as abdominal
pain and discomfort and altered bowel function, ranging
from diarrhoea-predominant IBS (IBS-D) to constipa-
tion-predominant IBS (IBS-C), in the absence of bio-
chemical or structural pathology.1 Patients are generally
considered to have IBS-D when their bowel movements
contain loose or watery stools ≥25% of the time and they
experience hard or lumpy stools <25% of the time, while
patients with IBS-C generally have hard or lumpy stools
>25% of the time and loose, watery stools <25% of the
time.2
Irritable bowel syndrome has a substantial negative
impact on patient quality of life and may affect between
1% to more than 20% of adults (depending on disease
deﬁnition and global geographical location). Furthermore,
IBS is one of the most common conditions managed by
primary care physicians and gastroenterologists world-
wide.1 Therefore, development of effective, well-tolerated
and safe IBS treatments is important. However, available
IBS therapies have limited efﬁcacy, while some conven-
tional IBS therapies are poorly tolerated in some patients
(e.g., ﬁbre products are more likely than placebo to pro-
duce bloating, and anti-spasmodics are more likely than
placebo to produce anti-cholinergic adverse effects).1, 3
The pathophysiology of IBS is believed to be multifac-
torial, and there is increasing evidence that small intesti-
nal bacterial overgrowth and changes in colonic
microﬂora may lead to IBS symptoms in some patients.4
Therefore, antibiotics have been proposed as a possible
treatment for IBS, and multiple randomised controlled
trials (RCTs) have assessed the efﬁcacy of rifaximin
(Xifaxan; Salix Pharmaceuticals, Inc., Raleigh, NC,
USA).5 Rifaximin is a nonsystemic oral antimicrobial
agent that is targeted to the gastrointestinal tract.6–8 Rif-
aximin is currently indicated for the treatment of travel-
lers’ diarrhoea caused by non-invasive strains of
Escherichia coli in patients aged ≥12 years and for
decreasing the risk of overt hepatic encephalopathy (HE)
recurrence in adults.8 Rifaximin is in clinical develop-
ment in the United States for the treatment of IBS-D,
although it has been studied in combined populations of
IBS-D and mixed-IBS, which has been characterised as
non–constipation-predominant IBS (non-C IBS).
Two identically designed, randomised, double-blind,
placebo-controlled, phase 3 trials (TARGET 1 and TAR-
GET 2) demonstrated that patients with non-C IBS
receiving rifaximin 550 mg three times daily for 2 weeks
were more likely to achieve adequate relief of global IBS
symptoms than those receiving placebo (40.7% vs.
31.7%, respectively; P < 0.001), as well as adequate relief
of IBS–related bloating (40.2% vs. 30.3%, P < 0.001) dur-
ing ≥2 of the ﬁrst 4 weeks post-treatment compared with
placebo.9 Furthermore, a signiﬁcantly greater percentage
of patients treated with rifaximin experienced adequate
relief of global symptoms of IBS throughout the 12-week
studies (2 weeks of treatment and 10 weeks of fol-
low-up).9 A phase 2b dose-ranging study also demon-
strated efﬁcacy of rifaximin vs. placebo in patients with
non-C IBS.10 In addition, a third phase 3 RCT (TAR-
GET 3), assessing the efﬁcacy and safety of repeated
courses of rifaximin 550 mg three times daily for the
management of IBS-D, is currently ongoing.11
Because less than 1% of rifaximin is absorbed systemi-
cally, the drug may be well tolerated with fewer systemic
adverse events.6 However, development of Clostridium
difﬁcile colitis and antimicrobial resistance are appropri-
ate concerns when antibiotics are used, especially because
long-term management of IBS with rifaximin may
require repeated courses of treatment. Although the
phase 2b and phase 3 RCTs did not address antibiotic
microbial resistance, these RCTs did collect detailed
safety and tolerability data that have not been previously
published. The objective of the current analysis was to
conduct a pooled safety and tolerability assessment of
rifaximin compared with placebo in the treatment of IBS
using data from the phase 2b and phase 3 trials.
METHODS
Study design and patient population
Data were pooled from one phase 2b (NCT00269412)
trial and two phase 3, double-blind, placebo-controlled
trials (NCT00731679 and NCT00724126) conducted in
the United States and Canada.9, 11 Information on the
study design and patient population for the two phase 3
trials has been previously published.7 In all three trials,
patients were ≥18 years of age and had a conﬁrmed
diagnosis of IBS using Rome II criteria and met criteria
for non-C IBS. The phase 2b and phase 3 trials excluded
patients with symptoms of constipation during the
≥7-day eligibility period. All phase 2b and phase 3 trial
protocols were approved by the institutional review
board or independent ethics committee for each study
site and all patients provided informed written consent.
In all three studies, the randomisation code was com-
puter generated and stratiﬁed by centre. Patients in the
phase 2b trial were randomised (2:1:2:1:1) to receive one
of the ﬁve following regimens: placebo twice daily for
4 weeks; rifaximin 275 mg twice daily for 2 weeks,
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followed by placebo for 2 weeks; rifaximin 550 mg twice
daily for 2 weeks, followed by placebo for 2 weeks; rifax-
imin 1100 mg twice daily for 2 weeks, followed by
placebo for 2 weeks; or rifaximin 550 mg twice daily
for 4 weeks. Patient follow-up visits were conducted
post-treatment for 12 weeks (i.e., 16-week study period).
Patients in the phase 3 trials were randomised (1:1) to
receive rifaximin 550 mg three times daily or placebo
three times daily for 2 weeks and followed 10 weeks
post-treatment (i.e., 12-week study period).9
Safety assessments
Safety parameters that were assessed in the studies
included overall adverse events (AEs), AEs resulting in
discontinuation from the study, serious AEs, gastrointes-
tinal-associated AEs, and infection-associated AEs. The
AEs were treatment-emergent and deﬁned as any AE
occurring on or after Day 1 of treatment (or, for
pre-existing conditions, worsening on or after Day 1). A
patient who had more than one incident of the same AE
was counted once for that event, according to the most
severe intensity of the event or the closest relationship
with treatment.
Analysis of pooled AE data was performed for the
overall evaluation period [treatment (2 or 4 weeks) plus
post-treatment (10 or 12 weeks) periods] and for the
treatment period only. AE severity was classiﬁed as mild,
moderate, severe, or not applicable. An AE was consid-
ered serious if life-threatening or resulting in death;
in-patient hospitalisation; or prolongation of existing
hospitalisation, disability or incapacity, congenital anom-
aly, or other event considered serious, based upon appro-
priate medical judgment.
In the phase 2b trial, AE data were collected and mea-
sured at randomisation and at weeks 1, 2, 4, 6, 8, 12,
and 16; laboratory tests (i.e., blood chemistry, haematol-
ogy, and urinalysis) were performed during screening
and at weeks 2 and 4; and physical examinations were
performed during screening and at week 4. Data on AEs
in the phase 3 trials were recorded at screening and
baseline and at weeks 1, 2, 4, 6, 8, 10, and 12. Physical
examinations and laboratory tests (i.e., blood chemistry,
haematology, urinalysis) were conducted at screening
and at weeks 2 and 12.
Statistical analyses
Safety data from the three trials were pooled and analysed
for all patients who received ≥1 dose of study medication
and included at least 1 post-baseline safety assessment
(safety population). Descriptive statistics were used, with
categorical variables summarised using counts and per-
centages and continuous variables summarised using
mean, standard deviation, minimum, and maximum.
RESULTS
Demographics
A total of 1940 patients were enrolled in the one phase
2b and two phase 3 rifaximin trials,9 and 1932 patients
were included in the safety population. Of these patients,
674 were treated in the phase 2b trial (479 treated with
rifaximin and 195 treated with placebo), and 1258 were
treated in the two phase 3 trials (624 treated with rifaxi-
min and 634 treated with placebo). Overall, approxi-
mately 89% of the patients were aged <65 years, and the
mean age was 46 years (Table 1). Approximately 73% of
the patients were female and approximately 92% of
patients were white. One hundred per cent of the
patients in the phase 3 rifaximin trials and 78% of the
patients in the phase 2b trial met criteria for IBS-D.
Safety
During the overall evaluation period (treatment phase
and post-treatment follow-up), the majority of AEs were
mild to moderate in intensity for both the rifaximin and
placebo groups. The overall safety proﬁle with rifaximin,
for both the all-rifaximin and the 550-mg pooled groups,
was comparable to the safety proﬁle for placebo
(Table 2). The incidence of any AEs, AEs considered by
the investigator to be drug-related, serious AEs and AEs
resulting in study discontinuation were similar between
both groups. No deaths occurred during the trials, and
none of the reports of serious AEs included ischaemic
colitis or constipation. There were no clinically signiﬁ-
cant changes from baseline in laboratory test ﬁndings in
the rifaximin-treated and placebo-treated patients.
The most common AEs experienced during the overall
evaluation period by patients in the rifaximin group
(pooled) and the placebo group, respectively, included
those associated with the gastrointestinal tract or with
infection, with upper respiratory tract infection and nau-
sea reported most often in the pooled rifaximin group
(Table 2).
Because gastrointestinal- and infection-associated AEs
were among the most common, an analysis of gastroin-
testinal- and infection-associated AEs by rifaximin dos-
age during the treatment period was conducted. The
incidence of gastrointestinal- and infection-associated
AEs occurring in ≥1% of patients was similar across the
range of rifaximin dosages and was comparable to that
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for placebo (Table 3). Among patients treated with rifax-
imin 550 mg three times daily, 10.9% experienced a gas-
trointestinal-associated AE during treatment; nausea,
abdominal pain, and ﬂatulence were most frequently
reported. This group also had the lowest reported inci-
dence of infection-associated AEs (5.1%) during treat-
ment compared with the other dosage groups, as well as
compared with the pooled rifaximin analysis.
In the IBS population overall, one patient had a C.
difﬁcile–positive stool culture at baseline; this patient
received study medication (rifaximin 550 mg twice daily)
until positive test results were obtained, prompting with-
drawal from the study due to the exclusion criteria (posi-
tive baseline stool culture result) being met. However, no
patient developed C. difﬁcile colitis, as determined via
stool testing during active treatment. Therefore, the rate
of C. difﬁcile colitis in the overall IBS population was
zero (no cases per 61.3 patient-years of exposure).
The incidence of constipation was low during the
treatment period for patients receiving rifaximin (0.7%,
pooled) and placebo (1.1%), as well as during the overall
evaluation period [rifaximin (1.1%, pooled) and placebo
(1.8%)]. Similarly, the incidence of worsening diarrhoea
was low and similar between the two groups during the
treatment period [rifaximin (1.4%, pooled) and placebo
(1.3%)] and during the overall evaluation period [rifaxi-
min (3.4%, pooled) and placebo (3.1%)].
DISCUSSION
Rifaximin is a nonsystemic, gastrointestinal-targeted anti-
biotic under clinical development for the treatment of
IBS. Per the American College of Gastroenterology evi-
dence-based position statement on the management of
IBS, ‘a short-term course of a non-absorbable antibiotic
is more effective than placebo for global improvement of
IBS and for bloating’.1 The position statement also noted
that ‘minimal safety data were reported. . .but rifaxi-
min-treated patients reportedly tolerated antibiotics with-
out severe adverse events’.1 Therefore, to better
understand the safety and tolerability of rifaximin for the
treatment of IBS, a pooled safety analysis of phase 2b
and phase 3 trials was conducted. These data represent
the most comprehensive report about the safety and tol-
erability of rifaximin in patients with IBS.
The incidence of all AEs, serious AEs, drug-related
AEs, AEs leading to study discontinuation, gastrointesti-
nal-associated AEs, and infection-associated AEs with
rifaximin was comparable to placebo during the overall
Table 1 | Patient demographics and baseline characteristics
Parameter
Rifaximin
Placebo
(n = 829)
275 mg
twice daily
2 weeks
(n = 95)
550 mg
twice daily
2 weeks
(n = 190)
550 mg
twice daily
4 weeks
(n = 96)
550 mg three
times daily
2 weeks
(n = 624)
1100 mg
twice daily
2 weeks
(n = 98)
Pooled
(n = 1103)
Age, years
Mean (s.d.) 47.7 (13.8) 44.6 (14.4) 46.5 (13.8) 46.0 (14.4) 45.6 (15.4) 45.9 (14.4) 46.2 (14.5)
Range 21–78 19–82 19–78 18–88 19–81 18–88 18–82
Age, n (%)
<65 years 83 (87.4) 170 (89.5) 86 (89.6) 560 (89.7) 87 (88.8) 986 (89.4) 732 (88.3)
≥65 years 12 (12.6) 20 (10.5) 10 (10.4) 64 (10.3) 11 (11.2) 117 (10.6) 97 (11.7)
Sex, n (%)
Male 14 (14.7) 54 (28.4) 22 (22.9) 162 (26.0) 25 (25.5) 277 (25.1) 239 (28.8)
Female 81 (85.3) 136 (71.6) 74 (77.1) 462 (74.0) 73 (74.5) 826 (74.9) 590 (71.2)
Race,* n (%)
Black 6 (6.3) 6 (3.2) 8 (8.3) 45 (7.2) 4 (4.1) 69 (6.3) 54 (6.5)
White 85 (89.5) 183 (96.3) 85 (88.5) 563 (90.2) 92 (93.9) 1008 (91.4) 764 (92.2)
Other 4 (4.2) 1 (0.5) 3 (3.1) 16 (2.6) 2 (2.0) 26 (2.4) 11 (1.3)
Mean duration of IBS
symptoms, years (s.d.)
NR† NR† NR† 6.1 (7.8) NR† NR† NR†
Mean daily bowel
movements, n (s.d.)
3.4 (1.9) 3.2 (1.9) 3.4 (2.2) 3.0 (1.5) 3.6 (2.0) 3.1 (1.7) 3.1 (1.5)
IBS, irritable bowel syndrome; NR, not reported; s.d., standard deviation.
* If >1 race was checked, the patient was included in the ‘Other’ category.
† Data were not collected in the phase 2b trial.
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evaluation period and during the treatment period. No
apparent dose-related increase in gastrointestinal-associ-
ated AEs or risk for infection emerged from the analysis.
Gastrointestinal-associated AEs were reported in 13.7%
of patients in the lowest rifaximin dose group and in
16.3% of patients in the highest rifaximin dose group.
Infection-associated AEs occurred in 16.8% of patients in
the lowest dose group and in 15.3% in the highest dose
group. No clear dose-related increase in individual gas-
trointestinal-associated or infection-associated AEs was
observed. This safety and tolerability proﬁle may result
from the low systemic absorption (<1%) of rifaximin.
These results are consistent with a published
meta-analysis of 5 double-blind, placebo-controlled tri-
als5 and additional smaller, prospective trials in which
rifaximin for the treatment of IBS was well tolerated.12–
15 In these studies, the incidence of AEs with rifaximin
was low, with no statistically signiﬁcant differences in
AEs for rifaximin-treated patients vs. placebo-treated
patients. Our study provides a more comprehensive
analysis by pooling data from the three largest RCTs,
while also providing data about additional individual
adverse events. The similarity in the incidence, intensity
and type of AEs reported for the rifaximin and placebo
groups in the current analysis supports the use of rifaxi-
min in this patient population when its short-term safety
and tolerability proﬁle is considered.
The chronic nature of IBS typically necessitates long-
term management strategies. In the case of rifaximin,
many patients may require repeated courses of rifaximin
and concerns have been raised about the risk of develop-
ment of C. difﬁcile infection with antimicrobial ther-
apy.16 Therefore, additional descriptive data and pooled
analyses from RCTs were performed to assess frequency
of C. difﬁcile colitis cases per patient-years of exposure
in multiple patient populations, including: (i) IBS; (ii)
HE using RCT and long-term open-label maintenance/
safety study data; and (iii) Crohn’s disease. In a single
phase 2 RCT of Crohn’s disease, 308 patients received
800–2400 mg/day of rifaximin extended intestinal release
for up to 12 weeks, totalling 59.2 patient-years of expo-
sure.17 One case of C. difﬁcile colitis was diagnosed in a
patient treated with rifaximin extended intestinal release
1600 mg/day at 20 days post-treatment. Therefore, in
the Crohn’s disease population, the rate of C. difﬁcile
colitis was 1.7 events per 100 patient-years of exposure.
Treatment of HE with rifaximin has been studied in a
6-month randomised, double-blind, placebo-controlled
trial18 and in a long-term (>3 years) open-label mainte-
nance trial of rifaximin 550 mg twice daily for the
prevention of HE recurrence.19, 20 In the RCT of patients
with cirrhosis and a history of HE, two cases of C. difﬁcile
colitis were diagnosed, and another four cases were diag-
nosed during the long-term open-label maintenance
study. Thus, six cases of C. difﬁcile colitis were diagnosed
in 508.5 patient-years of exposure, corresponding to a rate
of 1.2 events per 100 patient-years of exposure in the HE
population. Because patients with HE may be continu-
ously exposed to rifaximin to prevent disease recurrence,
are frequently hospitalised, and have multiple risk factors
for this condition, rates of C. difﬁcile colitis are expected
to be higher for patients with HE than for patients with
IBS. It should also be noted that rifaximin has potent
activity against most C. difﬁcile strains and has been
investigated as a potential treatment option.21–26
Concerns about development of microbial antibiotic
resistance with widespread and recurrent use of rifaximin
are understandable, although development of resistance
may be small, due to the mechanism of antibiotic resis-
tance with rifaximin. With many antibiotics, resistance is
transmitted by mobile genetic elements, such as plasmids
or transposons, which facilitate rapid development of
antibiotic resistance among a population of bacteria.
Antibiotic resistance to rifaximin appears to occur
through chromosomal mutation that blocks the ability of
the agent to inhibit bacterial DNA-dependent RNA
polymerase, and these mutations are rare.27 In patients
treated with rifaximin for 5 days, resistant bacterial
strains were recovered, but susceptibility to rifaximin
was regained 1–12 weeks after treatment discontinua-
tion.28 Also, in a placebo-controlled trial, no signiﬁcant
increases in antimicrobial resistance in Gram-positive or
Gram-negative bacteria were observed in patients treated
with rifaximin compared with patients receiving placebo
for 3 days.29 However, antibiotic resistance in patients
receiving rifaximin for the treatment of other gastrointes-
tinal diseases has been described.30, 31
There are a number of limitations of the current
analysis. For example, patients were treated with only a
single course of therapy, although management of rifaxi-
min for IBS will most likely require repeated courses of
treatment. Also, 100% of the patients in the phase 3
studies and 78% of the patients in the phase 2b trial met
criteria for IBS-D, so these data may be more applicable
to an IBS-D population instead of the non-C IBS popu-
lation. Additional limitations include: a risk of potential
bias of pooling data from phase 2 and phase 3 studies
with varied design, the small number of patients
included in the lower rifaximin dosage groups, the
limited extent of drug exposure, and the lack of
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minimum inhibitory concentration assessments of bacte-
rial strains isolated from rifaximin-exposed patients. The
ongoing TARGET 3 (retreatment) trial has measures
included in its study design that will help quantify rates
of microbial antibiotic resistance and disappearance in
bacterial strains isolated from patients with IBS who
have been exposed to multiple courses of rifaximin.11
In summary, under the conditions studied, rifaximin
appears to be safe and well tolerated in the treatment of
non-C IBS – with no increased risk of infections, includ-
ing C. difﬁcile infection and no substantial differences in
any AEs vs. placebo. This proﬁle would be a major bene-
ﬁt of rifaximin for treatment of IBS when used in appro-
priate subgroups of patients.
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Table 2 | Overall evaluation period adverse event proﬁle
Adverse event
Patients, n (%)
All-rifaximin
(pooled) (n = 1103)
Rifaximin 550 mg
(pooled) (n = 1008)
Placebo
(n = 829)
Any AE 579 (52.5) 529 (52.5) 436 (52.6)
Speciﬁc AE in ≥2% of patients*
Headache 59 (5.3) 55 (5.5) 51 (6.2)
URTI 50 (4.5) 45 (4.5) 47 (5.7)
Nausea 48 (4.4) 41 (4.1) 31 (3.7)
Abdominal pain 41 (3.7) 40 (4.0) 39 (4.7)
Diarrhoea 37 (3.4) 35 (3.5) 26 (3.1)
UTI 37 (3.4) 32 (3.2) 18 (2.2)
Nasopharyngitis 26 (2.4) 26 (2.6) 39 (4.7)
Sinusitis 24 (2.2) 23 (2.3) 23 (2.8)
Vomiting 22 (2.0) 20 (2.0) 12 (1.4)
Back pain 22 (2.0) 20 (2.0) 19 (2.3)
AE severity†
Mild 268 (24.3) 244 (24.2) 169 (20.4)
Moderate 246 (22.3) 225 (22.3) 214 (25.8)
Severe 63 (5.7) 58 (5.8) 53 (6.4)
Drug-related AEs 134 (12.1) 124 (12.3) 89 (10.7)
Serious AEs
Any serious AE 16 (1.5) 15 (1.5) 18 (2.2)
Drug-related serious AEs 1 (0.1) 1 (0.1) 2 (0.2)
Deaths 0 0 0
AEs resulting in study discontinuation
Any AE 22 (2.0) 19 (1.9) 14 (1.7)
Drug-related AE 9 (0.8) 9 (0.9) 7 (0.8)
AE, adverse event; URTI, upper respiratory tract infection; UTI, urinary tract infection.
* Occurring in ≥2% of patients in either rifaximin group or in placebo group.
† Data not available for 2 AEs in rifaximin groups.
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